首页> 外文OA文献 >Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma

【2h】

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma

机译：I50067的I相剂量升级研究，单独的人源化抗CXCR4单克隆抗体，并与Lenalidomide和低剂量地塞米松组合，复发或难治多骨髓瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Guillemette Fouquet; Stéphanie Guidez; Valentine Richez; Anne-Marie Stoppa; Christophe Le Tourneau; Margaret Macro; Cécile Gruchet; Arthur Bobin; Niels Moya; Thomas Syshenko; Florence Sabirou; Anthony Levy; Paul Franques; Hélène Gardeney; Lionel Karlin; Lotfi Benboubker; Monia Ouali; Jean-Claude Vedovato; Pierre Ferre; Mariya Pavlyuk; Michel Attal; Thierry Facon; Xavier Leleu;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma [J] . Ghobrial Irene M., Liu Chia-Jen, Perez Raymond P., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：新型抗CXCR4抗体Ulocuplumab（BMS-936564）的相IB / II研究与Lenalidomide加低剂量地塞米松，或用Bortezomib加上与复发或难倒多发性骨髓瘤的硼替佐米加上地塞米松
2. MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study [J] . Raab Marc S., Chatterjee Manik, Goldschmidt Hartmut, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Mor202与低剂量的地塞米松（DEX）或氯胺/德克斯或乙二胺/ DEX复发或难治性多发性多发性骨髓瘤（RRMM）：初步分析I / IIA，多中心，剂量升级研究
3. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma [J] . Shira Dinner, Tamara J. Dunn, Elizabeth Price, International journal of hematology . 2018,第3期

机译：I阶段I，开放标签，氨化蛋白的剂量升级研究与Lenalidomide和每周地塞米松组合在先前治疗的成年人中，复发或难治多骨髓瘤
4. Study of stability of expression of a humanized monoclonal antibody from a transfected NSO myeloma cell line using different culture media and serum concentrations [C] . CASTILLO A.J., VICTORES S., MARISON I.W Annual Meeting of the European Society of Animal Cell Technology . 1999

机译：使用不同培养基和血清浓度从转染的NSO骨髓瘤细胞中表达人源化单克隆抗体表达的稳定性研究
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Phase I dose-escalation study of F50067 a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma [O] . Guillemette Fouquet, Stéphanie Guidez, Valentine Richez, 2018

机译：F50067（一种人源化抗CXCR4单克隆抗体单独使用并与来那度胺和小剂量地塞米松联合使用）在复发或难治性多发性骨髓瘤中进行I期剂量递增研究
7. Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma [O] . Ruben Niesvizky, Thomas G. Martin, William I. Bensinger, 2013

机译：Carfilzomib，Lenalidomide和低剂量地塞米松的相IB剂量 - 升级研究（PX-171-006）在复发或进行多发性骨髓瘤中

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma

著录项

相似文献

相关主题

期刊订阅